Human Embryonic Stem Cell-derived M Cell

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Human Embryonic Stem Cell-derived M Cell
DrugBank Accession Number
DB15734
Background

CAStem is composed of immunity- and matrix-regulatory cells (IMRCs), also known as M cells, which can be administered through injection. These IMRCs are differentiated from human embryonic stem cells that are expanded and then harvested. These cells are currently being investigated against lung injury and fibrosis -- conditions which are outcomes of lung disorders including COVID-19. IMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. However, the difference comes with IMRCs displaying a higher quality of consistency, having stronger immunomodulatory and anti-fibrotic functions, and being stronger in potential treatment of lung injury and fibrosis.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • CAStem
  • immunity- and matrix-regulatory cells
  • Immunity-and-matrix-regulatory cells
  • IMRCs
  • M cells
External IDs
  • Human Embryonic Stem Cell-derived M Cell

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

IMRCs are different from cells such as the umbilical cord mesenchymal stem cells in gene expression profile; thus, this results in IMRCs possessing qualities such as higher expression levels of proliferative, immunomodulatory, and anti-fibrotic genes. Additionally, they have the ability to modulate immunity and regulate extracellular matrix production.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Wu J, Song D, Li Z, Guo B, Xiao Y, Liu W, Liang L, Feng C, Gao T, Chen Y, Li Y, Wang Z, Wen J, Yang S, Liu P, Wang L, Wang Y, Peng L, Stacey GN, Hu Z, Feng G, Li W, Huo Y, Jin R, Shyh-Chang N, Zhou Q, Wang L, Hu B, Dai H, Hao J: Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis. Cell Res. 2020 Jun 16. pii: 10.1038/s41422-020-0354-1. doi: 10.1038/s41422-020-0354-1. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingPreventionAdenovirus Infections / BK Virus Infection / Cytomegalovirus (CMV) Infection / Epstein Barr Virus Infections / Human Herpes Virus 6 Infection / JC virus infection1
1, 2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Lung Injury, Acute (ALI) / Respiratory Distress Syndrome, Acute (ARDS) / Virus; Pneumonia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 20:11 / Updated on August 13, 2020 07:02